Published in World J Transplant on April 24, 2012
Long-term outcome of ketoconazole and tacrolimus co-administration in kidney transplant patients. World J Nephrol (2014) 0.79
Comparison of the Effect of Alemtuzumab versus Standard Immune Induction on Early Kidney Allograft Function in Shiraz Transplant Center. Int J Organ Transplant Med (2015) 0.75
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med (2010) 6.26
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med (1998) 3.76
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 2.67
Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ (1999) 2.65
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 2.61
B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med (2009) 2.56
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 2.26
De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant (2009) 2.24
Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet (1997) 2.12
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med (1998) 1.81
Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation (2006) 1.81
A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation (2009) 1.79
Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant (2008) 1.67
A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation (2004) 1.58
Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group. Transplantation (1999) 1.29
Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction--long-term results. Am J Transplant (2005) 1.29
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation (2005) 1.25
Monoclonal antibody therapy. Anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation (1986) 1.24
Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant (2002) 1.23
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant (2005) 1.22
A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation (2003) 1.19
Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation (1992) 1.16
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant (2007) 1.12
Induction immunosuppression. Transplantation (2006) 1.10
Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation (2004) 1.07
Alemtuzumab (Campath-1H): a systematic review in organ transplantation. Transplantation (2006) 1.04
Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol (1986) 1.04
Long-term results of rabbit antithymocyte globulin and basiliximab induction. N Engl J Med (2008) 1.03
Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation (2002) 1.02
Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy (2006) 1.02
Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant (2005) 0.99
A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation (2008) 0.99
Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant (2008) 0.98
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation (2003) 0.97
Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation (2007) 0.96
Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant (2007) 0.96
Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation (2004) 0.93
Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. Transplantation (2008) 0.92
Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol (1997) 0.92
Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation (2008) 0.92
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant (2008) 0.91
Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int (2006) 0.91
Induction of immunosuppression with polyclonal antithymocyte globulins: an overview. Exp Clin Transplant (2003) 0.91
Complications and monitoring of OKT3 therapy. Am J Kidney Dis (1988) 0.91
The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther (2007) 0.91
Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy (2004) 0.89
Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation (2007) 0.89
Immunosuppressive drug-induced diabetes. Diabetes Metab (2006) 0.88
Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant (2006) 0.87
Efficacy and safety of tacrolimus compared with ciclosporin A in renal transplantation: three-year observational results. Nephrol Dial Transplant (2008) 0.85
Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant (1998) 0.85
Long-term outcome of adults who undergo transplantation with single pediatric kidneys: how young is too young? Clin J Am Soc Nephrol (2009) 0.84
Evaluation of low-dose rituximab induction therapy in living related kidney transplantation. Transplantation (2010) 0.84
Daclizumab. Expert Opin Biol Ther (2007) 0.82
Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant (2011) 0.82
The cost-effectiveness of induction immunosuppression in kidney transplantation. Nephrol Dial Transplant (2009) 0.81
Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy. Hematology (2005) 0.80
Long-term outcome of highly sensitized African American patients transplanted with deceased donor kidneys. Transpl Int (2010) 0.79
Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation (2007) 0.79
A comparison of long-term survivals of simultaneous pancreas-kidney transplant between African American and Caucasian recipients with basiliximab induction therapy. Am J Transplant (2007) 0.76
Evaluation of late immunologic parameters among renal transplant recipients induced with Campath-1H. Transplant Proc (2010) 0.76
OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant Proc (1993) 0.76
Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database. Am J Nephrol (2008) 0.76
Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation (2012) 2.10
Living donor kidney transplantation: medical, legal, and ethical considerations. South Med J (2007) 1.39
Laparoscopic procurement of single versus multiple artery kidney allografts: is long-term graft survival affected? Transplantation (2009) 0.92
Donor-recipient gender and size mismatch affects graft success after kidney transplantation. J Am Coll Surg (2010) 0.90
Hypertension and the metabolic syndrome. Am J Med Sci (2005) 0.86
Challenges of abdominal organ transplant in obesity. South Med J (2010) 0.83
Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp Nephrol (2009) 0.82
Hypertension in chronic dialysis patients: pathophysiology, monitoring, and treatment. Am J Med Sci (2003) 0.80
The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transplant (2010) 0.79
The effects of body mass index on graft survival in adult recipients transplanted with single pediatric kidneys. Am J Nephrol (2008) 0.79
Long-term outcome of highly sensitized African American patients transplanted with deceased donor kidneys. Transpl Int (2010) 0.79
Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci (2010) 0.79
Successful transplantation of HIV patients: the Louisiana experience. J La State Med Soc (2012) 0.78
Obesity and metabolic syndrome in kidney transplantation. Curr Hypertens Rep (2013) 0.76
Biodegradation-inspired bioproduction of methylacetoin and 2-methyl-2,3-butanediol. Sci Rep (2013) 0.75
Three organ transplant patients infected with 2009 novel H1N1 influenza in early fall, 2009. J La State Med Soc (2010) 0.75
Race and gender are not independent risk factors of allograft loss after kidney transplantation. Am J Surg (2010) 0.75
Who's your donor? Bringing about Louisiana's first domino paired exchange transplants. J La State Med Soc (2011) 0.75
Pancreas transplantation--a controversy in evolution. J La State Med Soc (2008) 0.75